Menu
Search
|

Menu

Close
X

Arcturus Therapeutics Ltd ARCT.OQ (NASDAQ Stock Exchange Global Market)

5.12 USD
-0.38 (-6.91%)
As of Mar 22
chart
Previous Close 5.50
Open 5.41
Volume 10,203
3m Avg Volume 8,965
Today’s High 5.41
Today’s Low 5.03
52 Week High 10.00
52 Week Low 4.11
Shares Outstanding (mil) 27.56
Market Capitalization (mil) 28.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
8
FY17
24
FY16
20
EPS (USD)
FY18
-2.065
FY17
-4.839
FY16
3.675
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
--
8.39
Price to Book (MRQ)
vs sector
0.71
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
16.02
LT Debt to Equity (MRQ)
vs sector
0.00
11.35
Return on Investment (TTM)
vs sector
-41.68
13.82
Return on Equity (TTM)
vs sector
-41.68
15.24

EXECUTIVE LEADERSHIP

Peter Farrell
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Joseph Payne
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Andrew Sassine
Chief Financial Officer, Director, Since 2019
Salary: --
Bonus: --
Pad Chivukula
Chief Operating Officer, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
Kevin Skol
Senior Vice President - Business Development & Alliance Management, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10628 Science Center Dr Ste 200
SAN DIEGO   CA   92121-1128

Phone: +1858.9002660

Arcturus Therapeutics Ltd is a ribonucleic acid (RNA) medicines company. The Company’s technology platform includes Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) and Unlocked Nucleomonomer Agent (UNA). The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Its versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The Company's proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes.

SPONSORED STORIES